BACKGROUND Streptokinase is a routinely used thrombolytic agent that is immunogenic and relatively inefficient toward platelet-rich thrombus, whereas staphylokinase is a poorly studied fibrinolytic agent. Here, the comparative immunogenicity and thrombolytic properties toward arterial platelet-rich thrombus and venous whole blood clots of streptokinase and recombinant staphylokinase were studie...

Limitations of CT Angiography in Patient Selection for Thrombolytic Therapy To the Editor: We have read with great interest the article by Wildermuth et al1 on the role of CT angiography (CTA) in patient selection for thrombolytic therapy. The authors report that selection of patients with little potential for benefit from thrombolytic therapy is feasible with the use of CTA. The CTA findings, ...

Limitations of CT Angiography in Patient Selection for Thrombolytic Therapy To the Editor: We have read with great interest the article by Wildermuth et al1 on the role of CT angiography (CTA) in patient selection for thrombolytic therapy. The authors report that selection of patients with little potential for benefit from thrombolytic therapy is feasible with the use of CTA. The CTA findings, ...

BACKGROUND AND PURPOSE Widespread use of thrombolytic treatments, along with improved chances of survival after an initial ischemic stroke, increases the possibility of repeated thrombolysis. There are few reports, however, regarding repeated thrombolysis in patients who have suffered acute ischemic stroke. We explored the number and outcome of patients with repeated thrombolytic therapy in the...

Do Not Substitute: IV Thrombolytic Selection Errors in Acute Stroke To the Editor: Activase (alteplase), commonly referred to as tPA, is a tissue-type plasminogen activator approved for treatment of ischemic stroke when given within 3 hours of symptom onset. Of the 6 thrombolytic drugs licensed for any use in the United States, Retaplase (reteplase), and TNKase (tenecteplase) share this mechani...

Thrombolytic therapy, also known as clot busting drug, is a breakthrough treatment which has saved untold lives. It has been used in the clinical area to treat venous and arterial thromboembolic complaints which are a foremost cause of death. In 1761, Morgagni lead the way of thrombolytic therapy. Now day's different types of thrombolytic drugs are currently available in market: alteplase, anis...

BACKGROUND Post-myocardial infarction ventricular septal defect (VSD) complicates approximately 2% of myocardial infarctions. Thrombolytic therapy may accelerate the time from myocardial infarction to VSD formation. The effects of thrombolytic therapy in patients with a post-myocardial infarction VSD were investigated. METHOD Demographic, procedural, and event data were retrospectively analys...

Summary. Examination and treatment of 274 patients with acute deep vein thrombosis the lower limbs (DVT) was carried out. Thrombolytic therapy (TLT) as a basic method used in 98 (35.8 %) patients. Of these, 44 (16.1 underwent catheter-guided thrombolysis 54 (19.7 systemic thrombolytic therapy. Anticoagulant (ACT) 176 (64.2 In distant period, positive results TLT significantly exceeded ACT. Thus...

Background: Thrombolytic therapy in patients with sub-massive pulmonary embolism (SMPTE) needs further assessment. Objectives: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. Patients andMethods: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and res...